nodes	percent_of_prediction	percent_of_DWPC	metapath
Zafirlukast—Tolvaptan—Vismodegib—skin cancer	0.553	1	CrCrCtD
Zafirlukast—ABCG2—Vismodegib—skin cancer	0.0492	0.13	CbGbCtD
Zafirlukast—ABCG2—Vemurafenib—skin cancer	0.0389	0.103	CbGbCtD
Zafirlukast—CYP1A2—Imiquimod—skin cancer	0.0292	0.0773	CbGbCtD
Zafirlukast—CYP2C8—Vismodegib—skin cancer	0.0262	0.0692	CbGbCtD
Zafirlukast—ABCG2—Dactinomycin—skin cancer	0.0258	0.0682	CbGbCtD
Zafirlukast—CYP2C19—Vismodegib—skin cancer	0.022	0.058	CbGbCtD
Zafirlukast—CYP2E1—Dacarbazine—skin cancer	0.0212	0.0561	CbGbCtD
Zafirlukast—CYP2C9—Vismodegib—skin cancer	0.0183	0.0483	CbGbCtD
Zafirlukast—ABCG2—Fluorouracil—skin cancer	0.0175	0.0461	CbGbCtD
Zafirlukast—CYP1A2—Vemurafenib—skin cancer	0.016	0.0423	CbGbCtD
Zafirlukast—CYP3A4—Imiquimod—skin cancer	0.0153	0.0405	CbGbCtD
Zafirlukast—CYP3A4—Temozolomide—skin cancer	0.0153	0.0405	CbGbCtD
Zafirlukast—ABCG2—Docetaxel—skin cancer	0.0133	0.0352	CbGbCtD
Zafirlukast—CYP2D6—Vemurafenib—skin cancer	0.0132	0.0349	CbGbCtD
Zafirlukast—CYP1A2—Dacarbazine—skin cancer	0.0123	0.0324	CbGbCtD
Zafirlukast—CYP3A4—Vismodegib—skin cancer	0.0106	0.0281	CbGbCtD
Zafirlukast—CYP2C8—Fluorouracil—skin cancer	0.0093	0.0246	CbGbCtD
Zafirlukast—CYP3A4—Vemurafenib—skin cancer	0.0084	0.0222	CbGbCtD
Zafirlukast—CYP1A2—Fluorouracil—skin cancer	0.0072	0.019	CbGbCtD
Zafirlukast—CYP2C9—Fluorouracil—skin cancer	0.00649	0.0171	CbGbCtD
Zafirlukast—CYP3A4—Docetaxel—skin cancer	0.00288	0.00761	CbGbCtD
Zafirlukast—Vasculitis—Vemurafenib—skin cancer	0.000929	0.0148	CcSEcCtD
Zafirlukast—CYSLTR2—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.000758	0.152	CbGpPWpGaD
Zafirlukast—Influenza like illness—Imiquimod—skin cancer	0.000751	0.012	CcSEcCtD
Zafirlukast—Digestion impaired—Temozolomide—skin cancer	0.000693	0.0111	CcSEcCtD
Zafirlukast—Raised liver function tests—Docetaxel—skin cancer	0.000668	0.0107	CcSEcCtD
Zafirlukast—Hepatotoxicity—Dactinomycin—skin cancer	0.000664	0.0106	CcSEcCtD
Zafirlukast—Hepatic function abnormal—Imiquimod—skin cancer	0.000642	0.0103	CcSEcCtD
Zafirlukast—Swelling—Imiquimod—skin cancer	0.000636	0.0102	CcSEcCtD
Zafirlukast—Back pain—Vismodegib—skin cancer	0.000621	0.00992	CcSEcCtD
Zafirlukast—Injury—Imiquimod—skin cancer	0.000611	0.00976	CcSEcCtD
Zafirlukast—Hepatotoxicity—Temozolomide—skin cancer	0.0006	0.00959	CcSEcCtD
Zafirlukast—Blister—Fluorouracil—skin cancer	0.000592	0.00947	CcSEcCtD
Zafirlukast—Eosinophilia—Vemurafenib—skin cancer	0.000563	0.009	CcSEcCtD
Zafirlukast—Liver injury—Temozolomide—skin cancer	0.000551	0.0088	CcSEcCtD
Zafirlukast—Arthralgia—Vismodegib—skin cancer	0.000546	0.00873	CcSEcCtD
Zafirlukast—Myalgia—Vismodegib—skin cancer	0.000546	0.00873	CcSEcCtD
Zafirlukast—CYSLTR1—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.000526	0.106	CbGpPWpGaD
Zafirlukast—Numbness—Fluorouracil—skin cancer	0.000515	0.00823	CcSEcCtD
Zafirlukast—Hyperbilirubinaemia—Temozolomide—skin cancer	0.00051	0.00814	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Vemurafenib—skin cancer	0.000497	0.00795	CcSEcCtD
Zafirlukast—Sensory loss—Fluorouracil—skin cancer	0.000493	0.00788	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Vismodegib—skin cancer	0.000477	0.00762	CcSEcCtD
Zafirlukast—Dyspepsia—Vismodegib—skin cancer	0.000461	0.00737	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Vismodegib—skin cancer	0.000452	0.00722	CcSEcCtD
Zafirlukast—Fatigue—Vismodegib—skin cancer	0.000452	0.00721	CcSEcCtD
Zafirlukast—Influenza like illness—Temozolomide—skin cancer	0.00045	0.00719	CcSEcCtD
Zafirlukast—Pain—Vismodegib—skin cancer	0.000448	0.00716	CcSEcCtD
Zafirlukast—Neuropathy—Temozolomide—skin cancer	0.000435	0.00695	CcSEcCtD
Zafirlukast—Injury—Bleomycin—skin cancer	0.000434	0.00693	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Vismodegib—skin cancer	0.000428	0.00684	CcSEcCtD
Zafirlukast—Throat sore—Docetaxel—skin cancer	0.000428	0.00683	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Imiquimod—skin cancer	0.000424	0.00678	CcSEcCtD
Zafirlukast—Oropharyngeal discomfort—Docetaxel—skin cancer	0.000424	0.00677	CcSEcCtD
Zafirlukast—Abdominal pain—Vismodegib—skin cancer	0.000414	0.00662	CcSEcCtD
Zafirlukast—Hepatic failure—Dactinomycin—skin cancer	0.000414	0.00661	CcSEcCtD
Zafirlukast—Sinusitis—Imiquimod—skin cancer	0.000406	0.00649	CcSEcCtD
Zafirlukast—Hepatotoxicity—Docetaxel—skin cancer	0.000399	0.00638	CcSEcCtD
Zafirlukast—Haemoglobin—Imiquimod—skin cancer	0.00039	0.00624	CcSEcCtD
Zafirlukast—Haemorrhage—Imiquimod—skin cancer	0.000388	0.00621	CcSEcCtD
Zafirlukast—Back pain—Vemurafenib—skin cancer	0.000383	0.00613	CcSEcCtD
Zafirlukast—Asthenia—Vismodegib—skin cancer	0.000376	0.006	CcSEcCtD
Zafirlukast—Hepatic failure—Temozolomide—skin cancer	0.000374	0.00598	CcSEcCtD
Zafirlukast—Pruritus—Vismodegib—skin cancer	0.000371	0.00592	CcSEcCtD
Zafirlukast—Diarrhoea—Vismodegib—skin cancer	0.000358	0.00573	CcSEcCtD
Zafirlukast—Swelling—Fluorouracil—skin cancer	0.000351	0.00561	CcSEcCtD
Zafirlukast—Liver function test abnormal—Dactinomycin—skin cancer	0.000343	0.00549	CcSEcCtD
Zafirlukast—Oropharyngeal pain—Docetaxel—skin cancer	0.000339	0.00542	CcSEcCtD
Zafirlukast—Hyperbilirubinaemia—Docetaxel—skin cancer	0.000339	0.00542	CcSEcCtD
Zafirlukast—Arthralgia—Vemurafenib—skin cancer	0.000338	0.00539	CcSEcCtD
Zafirlukast—Myalgia—Vemurafenib—skin cancer	0.000338	0.00539	CcSEcCtD
Zafirlukast—Vomiting—Vismodegib—skin cancer	0.000333	0.00532	CcSEcCtD
Zafirlukast—Rash—Vismodegib—skin cancer	0.00033	0.00528	CcSEcCtD
Zafirlukast—Dermatitis—Vismodegib—skin cancer	0.00033	0.00527	CcSEcCtD
Zafirlukast—Back pain—Imiquimod—skin cancer	0.000327	0.00523	CcSEcCtD
Zafirlukast—Dermatitis bullous—Fluorouracil—skin cancer	0.000324	0.00518	CcSEcCtD
Zafirlukast—Infection—Vemurafenib—skin cancer	0.000321	0.00514	CcSEcCtD
Zafirlukast—Ill-defined disorder—Imiquimod—skin cancer	0.000314	0.00501	CcSEcCtD
Zafirlukast—Nausea—Vismodegib—skin cancer	0.000311	0.00497	CcSEcCtD
Zafirlukast—Angioedema—Imiquimod—skin cancer	0.000309	0.00494	CcSEcCtD
Zafirlukast—Malaise—Imiquimod—skin cancer	0.000305	0.00487	CcSEcCtD
Zafirlukast—Neutropenia—Dactinomycin—skin cancer	0.000301	0.0048	CcSEcCtD
Zafirlukast—Influenza like illness—Docetaxel—skin cancer	0.000299	0.00478	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000295	0.00471	CcSEcCtD
Zafirlukast—Neuropathy—Docetaxel—skin cancer	0.000289	0.00462	CcSEcCtD
Zafirlukast—Arthralgia—Imiquimod—skin cancer	0.000288	0.0046	CcSEcCtD
Zafirlukast—Myalgia—Imiquimod—skin cancer	0.000288	0.0046	CcSEcCtD
Zafirlukast—Discomfort—Imiquimod—skin cancer	0.000284	0.00454	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000279	0.00446	CcSEcCtD
Zafirlukast—Fatigue—Vemurafenib—skin cancer	0.000279	0.00446	CcSEcCtD
Zafirlukast—Haemoglobin—Bleomycin—skin cancer	0.000277	0.00443	CcSEcCtD
Zafirlukast—Oedema—Imiquimod—skin cancer	0.000276	0.00441	CcSEcCtD
Zafirlukast—Haemorrhage—Bleomycin—skin cancer	0.000276	0.00441	CcSEcCtD
Zafirlukast—Hypoaesthesia—Bleomycin—skin cancer	0.000275	0.00439	CcSEcCtD
Zafirlukast—Infection—Imiquimod—skin cancer	0.000274	0.00438	CcSEcCtD
Zafirlukast—Neutropenia—Temozolomide—skin cancer	0.000272	0.00434	CcSEcCtD
Zafirlukast—Agranulocytosis—Dactinomycin—skin cancer	0.000268	0.00427	CcSEcCtD
Zafirlukast—Eosinophilia—Fluorouracil—skin cancer	0.000265	0.00424	CcSEcCtD
Zafirlukast—Hepatitis—Dactinomycin—skin cancer	0.000257	0.00411	CcSEcCtD
Zafirlukast—Body temperature increased—Vemurafenib—skin cancer	0.000256	0.00409	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Temozolomide—skin cancer	0.000254	0.00406	CcSEcCtD
Zafirlukast—Swelling—Docetaxel—skin cancer	0.000254	0.00405	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000251	0.00402	CcSEcCtD
Zafirlukast—Insomnia—Imiquimod—skin cancer	0.00025	0.00399	CcSEcCtD
Zafirlukast—Hepatic failure—Docetaxel—skin cancer	0.000249	0.00398	CcSEcCtD
Zafirlukast—Sinusitis—Temozolomide—skin cancer	0.000243	0.00389	CcSEcCtD
Zafirlukast—Dyspepsia—Imiquimod—skin cancer	0.000243	0.00388	CcSEcCtD
Zafirlukast—Hypersensitivity—Vemurafenib—skin cancer	0.000238	0.00381	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Imiquimod—skin cancer	0.000238	0.00381	CcSEcCtD
Zafirlukast—Fatigue—Imiquimod—skin cancer	0.000238	0.0038	CcSEcCtD
Zafirlukast—Pain—Imiquimod—skin cancer	0.000236	0.00377	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Fluorouracil—skin cancer	0.000234	0.00374	CcSEcCtD
Zafirlukast—Dermatitis bullous—Docetaxel—skin cancer	0.000234	0.00374	CcSEcCtD
Zafirlukast—Haemoglobin—Temozolomide—skin cancer	0.000234	0.00374	CcSEcCtD
Zafirlukast—Haemorrhage—Temozolomide—skin cancer	0.000233	0.00372	CcSEcCtD
Zafirlukast—Hepatitis—Temozolomide—skin cancer	0.000233	0.00372	CcSEcCtD
Zafirlukast—Asthenia—Vemurafenib—skin cancer	0.000232	0.00371	CcSEcCtD
Zafirlukast—Hypoaesthesia—Temozolomide—skin cancer	0.000232	0.0037	CcSEcCtD
Zafirlukast—Pruritus—Vemurafenib—skin cancer	0.000229	0.00366	CcSEcCtD
Zafirlukast—Feeling abnormal—Imiquimod—skin cancer	0.000227	0.00363	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Imiquimod—skin cancer	0.000226	0.00361	CcSEcCtD
Zafirlukast—Sinusitis—Fluorouracil—skin cancer	0.000224	0.00358	CcSEcCtD
Zafirlukast—Agranulocytosis—Fluorouracil—skin cancer	0.000223	0.00356	CcSEcCtD
Zafirlukast—Ill-defined disorder—Bleomycin—skin cancer	0.000223	0.00356	CcSEcCtD
Zafirlukast—Diarrhoea—Vemurafenib—skin cancer	0.000221	0.00354	CcSEcCtD
Zafirlukast—Urticaria—Imiquimod—skin cancer	0.000219	0.0035	CcSEcCtD
Zafirlukast—Abdominal pain—Imiquimod—skin cancer	0.000218	0.00349	CcSEcCtD
Zafirlukast—Body temperature increased—Imiquimod—skin cancer	0.000218	0.00349	CcSEcCtD
Zafirlukast—Malaise—Bleomycin—skin cancer	0.000217	0.00346	CcSEcCtD
Zafirlukast—Haemoglobin—Fluorouracil—skin cancer	0.000216	0.00344	CcSEcCtD
Zafirlukast—Haemorrhage—Fluorouracil—skin cancer	0.000214	0.00343	CcSEcCtD
Zafirlukast—Dizziness—Vemurafenib—skin cancer	0.000214	0.00342	CcSEcCtD
Zafirlukast—Hypoaesthesia—Fluorouracil—skin cancer	0.000213	0.00341	CcSEcCtD
Zafirlukast—Ill-defined disorder—Dactinomycin—skin cancer	0.000208	0.00332	CcSEcCtD
Zafirlukast—Liver function test abnormal—Docetaxel—skin cancer	0.000207	0.0033	CcSEcCtD
Zafirlukast—Vomiting—Vemurafenib—skin cancer	0.000206	0.00329	CcSEcCtD
Zafirlukast—Myalgia—Bleomycin—skin cancer	0.000204	0.00327	CcSEcCtD
Zafirlukast—Rash—Vemurafenib—skin cancer	0.000204	0.00326	CcSEcCtD
Zafirlukast—Dermatitis—Vemurafenib—skin cancer	0.000204	0.00326	CcSEcCtD
Zafirlukast—Hypersensitivity—Imiquimod—skin cancer	0.000203	0.00325	CcSEcCtD
Zafirlukast—Headache—Vemurafenib—skin cancer	0.000203	0.00324	CcSEcCtD
Zafirlukast—Discomfort—Bleomycin—skin cancer	0.000202	0.00323	CcSEcCtD
Zafirlukast—Malaise—Dactinomycin—skin cancer	0.000202	0.00323	CcSEcCtD
Zafirlukast—Asthenia—Imiquimod—skin cancer	0.000198	0.00316	CcSEcCtD
Zafirlukast—Oedema—Bleomycin—skin cancer	0.000196	0.00313	CcSEcCtD
Zafirlukast—Back pain—Temozolomide—skin cancer	0.000196	0.00313	CcSEcCtD
Zafirlukast—Pruritus—Imiquimod—skin cancer	0.000195	0.00312	CcSEcCtD
Zafirlukast—Infection—Bleomycin—skin cancer	0.000195	0.00311	CcSEcCtD
Zafirlukast—Nausea—Vemurafenib—skin cancer	0.000192	0.00307	CcSEcCtD
Zafirlukast—Thrombocytopenia—Bleomycin—skin cancer	0.000192	0.00307	CcSEcCtD
Zafirlukast—Myalgia—Dactinomycin—skin cancer	0.000191	0.00305	CcSEcCtD
Zafirlukast—Diarrhoea—Imiquimod—skin cancer	0.000189	0.00302	CcSEcCtD
Zafirlukast—Discomfort—Dactinomycin—skin cancer	0.000188	0.00301	CcSEcCtD
Zafirlukast—Ill-defined disorder—Temozolomide—skin cancer	0.000188	0.003	CcSEcCtD
Zafirlukast—Angioedema—Temozolomide—skin cancer	0.000185	0.00296	CcSEcCtD
Zafirlukast—Oedema—Dactinomycin—skin cancer	0.000183	0.00292	CcSEcCtD
Zafirlukast—Malaise—Temozolomide—skin cancer	0.000183	0.00292	CcSEcCtD
Zafirlukast—Dizziness—Imiquimod—skin cancer	0.000182	0.00292	CcSEcCtD
Zafirlukast—Infection—Dactinomycin—skin cancer	0.000182	0.0029	CcSEcCtD
Zafirlukast—Neutropenia—Docetaxel—skin cancer	0.000181	0.00289	CcSEcCtD
Zafirlukast—Thrombocytopenia—Dactinomycin—skin cancer	0.000179	0.00286	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000179	0.00285	CcSEcCtD
Zafirlukast—Vomiting—Imiquimod—skin cancer	0.000175	0.0028	CcSEcCtD
Zafirlukast—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000175	0.0352	CbGpPWpGaD
Zafirlukast—Rash—Imiquimod—skin cancer	0.000174	0.00278	CcSEcCtD
Zafirlukast—Dermatitis—Imiquimod—skin cancer	0.000174	0.00278	CcSEcCtD
Zafirlukast—Headache—Imiquimod—skin cancer	0.000173	0.00276	CcSEcCtD
Zafirlukast—Arthralgia—Temozolomide—skin cancer	0.000173	0.00276	CcSEcCtD
Zafirlukast—Myalgia—Temozolomide—skin cancer	0.000173	0.00276	CcSEcCtD
Zafirlukast—Discomfort—Temozolomide—skin cancer	0.00017	0.00272	CcSEcCtD
Zafirlukast—Neuropathy peripheral—Docetaxel—skin cancer	0.000169	0.0027	CcSEcCtD
Zafirlukast—Jaundice—Docetaxel—skin cancer	0.000168	0.00269	CcSEcCtD
Zafirlukast—Pain—Bleomycin—skin cancer	0.000168	0.00268	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000167	0.00266	CcSEcCtD
Zafirlukast—Oedema—Temozolomide—skin cancer	0.000165	0.00264	CcSEcCtD
Zafirlukast—Infection—Temozolomide—skin cancer	0.000164	0.00263	CcSEcCtD
Zafirlukast—Nausea—Imiquimod—skin cancer	0.000164	0.00262	CcSEcCtD
Zafirlukast—Thrombocytopenia—Temozolomide—skin cancer	0.000162	0.00259	CcSEcCtD
Zafirlukast—Feeling abnormal—Bleomycin—skin cancer	0.000162	0.00258	CcSEcCtD
Zafirlukast—Agranulocytosis—Docetaxel—skin cancer	0.000161	0.00257	CcSEcCtD
Zafirlukast—Myalgia—Fluorouracil—skin cancer	0.000159	0.00254	CcSEcCtD
Zafirlukast—Fatigue—Dactinomycin—skin cancer	0.000158	0.00252	CcSEcCtD
Zafirlukast—Discomfort—Fluorouracil—skin cancer	0.000157	0.00251	CcSEcCtD
Zafirlukast—Pain—Dactinomycin—skin cancer	0.000156	0.0025	CcSEcCtD
Zafirlukast—Urticaria—Bleomycin—skin cancer	0.000156	0.00249	CcSEcCtD
Zafirlukast—Haemoglobin—Docetaxel—skin cancer	0.000156	0.00249	CcSEcCtD
Zafirlukast—Body temperature increased—Bleomycin—skin cancer	0.000155	0.00248	CcSEcCtD
Zafirlukast—Haemorrhage—Docetaxel—skin cancer	0.000155	0.00247	CcSEcCtD
Zafirlukast—Hepatitis—Docetaxel—skin cancer	0.000155	0.00247	CcSEcCtD
Zafirlukast—Hypoaesthesia—Docetaxel—skin cancer	0.000154	0.00246	CcSEcCtD
Zafirlukast—Oedema—Fluorouracil—skin cancer	0.000152	0.00243	CcSEcCtD
Zafirlukast—Infection—Fluorouracil—skin cancer	0.000151	0.00242	CcSEcCtD
Zafirlukast—Feeling abnormal—Dactinomycin—skin cancer	0.000151	0.00241	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000151	0.00241	CcSEcCtD
Zafirlukast—Insomnia—Temozolomide—skin cancer	0.00015	0.00239	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Dactinomycin—skin cancer	0.00015	0.00239	CcSEcCtD
Zafirlukast—Thrombocytopenia—Fluorouracil—skin cancer	0.000149	0.00238	CcSEcCtD
Zafirlukast—Dyspepsia—Temozolomide—skin cancer	0.000146	0.00233	CcSEcCtD
Zafirlukast—Abdominal pain—Dactinomycin—skin cancer	0.000145	0.00231	CcSEcCtD
Zafirlukast—Body temperature increased—Dactinomycin—skin cancer	0.000145	0.00231	CcSEcCtD
Zafirlukast—Hypersensitivity—Bleomycin—skin cancer	0.000144	0.00231	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Temozolomide—skin cancer	0.000143	0.00228	CcSEcCtD
Zafirlukast—Fatigue—Temozolomide—skin cancer	0.000143	0.00228	CcSEcCtD
Zafirlukast—Pain—Temozolomide—skin cancer	0.000141	0.00226	CcSEcCtD
Zafirlukast—Asthenia—Bleomycin—skin cancer	0.000141	0.00225	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000139	0.00222	CcSEcCtD
Zafirlukast—Pruritus—Bleomycin—skin cancer	0.000139	0.00222	CcSEcCtD
Zafirlukast—Insomnia—Fluorouracil—skin cancer	0.000138	0.0022	CcSEcCtD
Zafirlukast—Feeling abnormal—Temozolomide—skin cancer	0.000136	0.00218	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Temozolomide—skin cancer	0.000135	0.00216	CcSEcCtD
Zafirlukast—Hypersensitivity—Dactinomycin—skin cancer	0.000135	0.00215	CcSEcCtD
Zafirlukast—Dyspepsia—Fluorouracil—skin cancer	0.000134	0.00214	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000132	0.0021	CcSEcCtD
Zafirlukast—Urticaria—Temozolomide—skin cancer	0.000131	0.0021	CcSEcCtD
Zafirlukast—Asthenia—Dactinomycin—skin cancer	0.000131	0.0021	CcSEcCtD
Zafirlukast—Abdominal pain—Temozolomide—skin cancer	0.000131	0.00209	CcSEcCtD
Zafirlukast—Body temperature increased—Temozolomide—skin cancer	0.000131	0.00209	CcSEcCtD
Zafirlukast—Back pain—Docetaxel—skin cancer	0.00013	0.00208	CcSEcCtD
Zafirlukast—Pain—Fluorouracil—skin cancer	0.00013	0.00208	CcSEcCtD
Zafirlukast—Feeling abnormal—Fluorouracil—skin cancer	0.000126	0.00201	CcSEcCtD
Zafirlukast—Diarrhoea—Dactinomycin—skin cancer	0.000125	0.002	CcSEcCtD
Zafirlukast—Vomiting—Bleomycin—skin cancer	0.000125	0.00199	CcSEcCtD
Zafirlukast—Rash—Bleomycin—skin cancer	0.000124	0.00198	CcSEcCtD
Zafirlukast—Dermatitis—Bleomycin—skin cancer	0.000123	0.00197	CcSEcCtD
Zafirlukast—Hypersensitivity—Temozolomide—skin cancer	0.000122	0.00195	CcSEcCtD
Zafirlukast—Urticaria—Fluorouracil—skin cancer	0.000121	0.00193	CcSEcCtD
Zafirlukast—Body temperature increased—Fluorouracil—skin cancer	0.00012	0.00192	CcSEcCtD
Zafirlukast—Asthenia—Temozolomide—skin cancer	0.000119	0.0019	CcSEcCtD
Zafirlukast—CYSLTR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000118	0.0238	CbGpPWpGaD
Zafirlukast—Pruritus—Temozolomide—skin cancer	0.000117	0.00187	CcSEcCtD
Zafirlukast—Nausea—Bleomycin—skin cancer	0.000116	0.00186	CcSEcCtD
Zafirlukast—Vomiting—Dactinomycin—skin cancer	0.000116	0.00186	CcSEcCtD
Zafirlukast—Rash—Dactinomycin—skin cancer	0.000115	0.00184	CcSEcCtD
Zafirlukast—CYSLTR2—female reproductive system—skin cancer	0.000115	0.19	CbGeAlD
Zafirlukast—Arthralgia—Docetaxel—skin cancer	0.000115	0.00183	CcSEcCtD
Zafirlukast—Myalgia—Docetaxel—skin cancer	0.000115	0.00183	CcSEcCtD
Zafirlukast—Diarrhoea—Temozolomide—skin cancer	0.000113	0.00181	CcSEcCtD
Zafirlukast—Hypersensitivity—Fluorouracil—skin cancer	0.000112	0.00179	CcSEcCtD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000111	0.0223	CbGpPWpGaD
Zafirlukast—Oedema—Docetaxel—skin cancer	0.00011	0.00176	CcSEcCtD
Zafirlukast—Dizziness—Temozolomide—skin cancer	0.000109	0.00175	CcSEcCtD
Zafirlukast—Infection—Docetaxel—skin cancer	0.000109	0.00175	CcSEcCtD
Zafirlukast—Nausea—Dactinomycin—skin cancer	0.000109	0.00174	CcSEcCtD
Zafirlukast—Pruritus—Fluorouracil—skin cancer	0.000108	0.00172	CcSEcCtD
Zafirlukast—Thrombocytopenia—Docetaxel—skin cancer	0.000108	0.00172	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR ligand binding—PTCH2—skin cancer	0.000107	0.0215	CbGpPWpGaD
Zafirlukast—Vomiting—Temozolomide—skin cancer	0.000105	0.00168	CcSEcCtD
Zafirlukast—Rash—Temozolomide—skin cancer	0.000104	0.00167	CcSEcCtD
Zafirlukast—Diarrhoea—Fluorouracil—skin cancer	0.000104	0.00167	CcSEcCtD
Zafirlukast—Dermatitis—Temozolomide—skin cancer	0.000104	0.00166	CcSEcCtD
Zafirlukast—Headache—Temozolomide—skin cancer	0.000104	0.00166	CcSEcCtD
Zafirlukast—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000101	0.0204	CbGpPWpGaD
Zafirlukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000101	0.0204	CbGpPWpGaD
Zafirlukast—Dizziness—Fluorouracil—skin cancer	0.000101	0.00161	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Docetaxel—skin cancer	0.0001	0.0016	CcSEcCtD
Zafirlukast—Insomnia—Docetaxel—skin cancer	9.95e-05	0.00159	CcSEcCtD
Zafirlukast—Nausea—Temozolomide—skin cancer	9.82e-05	0.00157	CcSEcCtD
Zafirlukast—Vomiting—Fluorouracil—skin cancer	9.69e-05	0.00155	CcSEcCtD
Zafirlukast—Dyspepsia—Docetaxel—skin cancer	9.68e-05	0.00155	CcSEcCtD
Zafirlukast—Rash—Fluorouracil—skin cancer	9.61e-05	0.00154	CcSEcCtD
Zafirlukast—Dermatitis—Fluorouracil—skin cancer	9.6e-05	0.00153	CcSEcCtD
Zafirlukast—Headache—Fluorouracil—skin cancer	9.54e-05	0.00153	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Docetaxel—skin cancer	9.49e-05	0.00152	CcSEcCtD
Zafirlukast—Fatigue—Docetaxel—skin cancer	9.48e-05	0.00151	CcSEcCtD
Zafirlukast—Pain—Docetaxel—skin cancer	9.4e-05	0.0015	CcSEcCtD
Zafirlukast—Feeling abnormal—Docetaxel—skin cancer	9.06e-05	0.00145	CcSEcCtD
Zafirlukast—Nausea—Fluorouracil—skin cancer	9.05e-05	0.00145	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Docetaxel—skin cancer	8.99e-05	0.00144	CcSEcCtD
Zafirlukast—Abdominal pain—Docetaxel—skin cancer	8.69e-05	0.00139	CcSEcCtD
Zafirlukast—Body temperature increased—Docetaxel—skin cancer	8.69e-05	0.00139	CcSEcCtD
Zafirlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	8.21e-05	0.0165	CbGpPWpGaD
Zafirlukast—Hypersensitivity—Docetaxel—skin cancer	8.1e-05	0.00129	CcSEcCtD
Zafirlukast—Asthenia—Docetaxel—skin cancer	7.89e-05	0.00126	CcSEcCtD
Zafirlukast—CYSLTR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	7.79e-05	0.0157	CbGpPWpGaD
Zafirlukast—Pruritus—Docetaxel—skin cancer	7.78e-05	0.00124	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR ligand binding—MC1R—skin cancer	7.73e-05	0.0155	CbGpPWpGaD
Zafirlukast—Diarrhoea—Docetaxel—skin cancer	7.52e-05	0.0012	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR ligand binding—PTCH2—skin cancer	7.41e-05	0.0149	CbGpPWpGaD
Zafirlukast—Dizziness—Docetaxel—skin cancer	7.27e-05	0.00116	CcSEcCtD
Zafirlukast—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—skin cancer	7.04e-05	0.0142	CbGpPWpGaD
Zafirlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	7.03e-05	0.0141	CbGpPWpGaD
Zafirlukast—Vomiting—Docetaxel—skin cancer	6.99e-05	0.00112	CcSEcCtD
Zafirlukast—Rash—Docetaxel—skin cancer	6.93e-05	0.00111	CcSEcCtD
Zafirlukast—Dermatitis—Docetaxel—skin cancer	6.93e-05	0.00111	CcSEcCtD
Zafirlukast—Headache—Docetaxel—skin cancer	6.89e-05	0.0011	CcSEcCtD
Zafirlukast—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	6.67e-05	0.0134	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—RHOU—skin cancer	6.63e-05	0.0133	CbGpPWpGaD
Zafirlukast—Nausea—Docetaxel—skin cancer	6.53e-05	0.00104	CcSEcCtD
Zafirlukast—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	6.16e-05	0.0124	CbGpPWpGaD
Zafirlukast—PTGS1—Overview of nanoparticle effects—PTGS2—skin cancer	5.52e-05	0.0111	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—SHH—skin cancer	5.5e-05	0.0111	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—PTCH2—skin cancer	5.48e-05	0.011	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	5.4e-05	0.0109	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—MC1R—skin cancer	5.36e-05	0.0108	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—SMO—skin cancer	5.22e-05	0.0105	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—PTCH1—skin cancer	5.22e-05	0.0105	CbGpPWpGaD
Zafirlukast—CYSLTR2—Endothelins—HRAS—skin cancer	5.17e-05	0.0104	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—PTGER4—skin cancer	5.08e-05	0.0102	CbGpPWpGaD
Zafirlukast—CYSLTR1—mammalian vulva—skin cancer	5.06e-05	0.0837	CbGeAlD
Zafirlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	4.62e-05	0.0093	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—RHOU—skin cancer	4.6e-05	0.00925	CbGpPWpGaD
Zafirlukast—PTGS1—Eicosanoid Synthesis—PTGS2—skin cancer	4.58e-05	0.0092	CbGpPWpGaD
Zafirlukast—CYSLTR1—lymphoid tissue—skin cancer	4.49e-05	0.0743	CbGeAlD
Zafirlukast—CYSLTR2—GPCR downstream signaling—MC1R—skin cancer	4.37e-05	0.00878	CbGpPWpGaD
Zafirlukast—CYSLTR1—female reproductive system—skin cancer	4.33e-05	0.0716	CbGeAlD
Zafirlukast—CYSLTR2—Signaling by GPCR—MC1R—skin cancer	3.96e-05	0.00797	CbGpPWpGaD
Zafirlukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	3.83e-05	0.0077	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—SHH—skin cancer	3.82e-05	0.00767	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—PTCH2—skin cancer	3.8e-05	0.00764	CbGpPWpGaD
Zafirlukast—CYSLTR1—head—skin cancer	3.62e-05	0.0599	CbGeAlD
Zafirlukast—CYSLTR1—GPCR ligand binding—SMO—skin cancer	3.62e-05	0.00727	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—PTCH1—skin cancer	3.62e-05	0.00727	CbGpPWpGaD
Zafirlukast—CYSLTR1—Endothelins—HRAS—skin cancer	3.58e-05	0.0072	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—PTGER4—skin cancer	3.52e-05	0.00708	CbGpPWpGaD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	3.32e-05	0.00667	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—PTCH2—skin cancer	3.24e-05	0.00651	CbGpPWpGaD
Zafirlukast—PTGS1—endothelium—skin cancer	3.16e-05	0.0522	CbGeAlD
Zafirlukast—CYSLTR1—GPCR downstream signaling—MC1R—skin cancer	3.03e-05	0.00609	CbGpPWpGaD
Zafirlukast—PTGS1—Overview of nanoparticle effects—IL6—skin cancer	3.01e-05	0.00604	CbGpPWpGaD
Zafirlukast—PTGS1—blood vessel—skin cancer	2.91e-05	0.0482	CbGeAlD
Zafirlukast—CYSLTR2—GPCR downstream signaling—PTGER4—skin cancer	2.87e-05	0.00577	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—SHH—skin cancer	2.83e-05	0.00568	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—MC1R—skin cancer	2.75e-05	0.00553	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—PTCH1—skin cancer	2.68e-05	0.00539	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—SMO—skin cancer	2.68e-05	0.00539	CbGpPWpGaD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	2.65e-05	0.00532	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—PTGER4—skin cancer	2.61e-05	0.00524	CbGpPWpGaD
Zafirlukast—PTGS1—Arachidonic acid metabolism—PTGS2—skin cancer	2.54e-05	0.00512	CbGpPWpGaD
Zafirlukast—CYSLTR1—lymph node—skin cancer	2.53e-05	0.0419	CbGeAlD
Zafirlukast—CYSLTR2—Signaling Pathways—GLI2—skin cancer	2.46e-05	0.00494	CbGpPWpGaD
Zafirlukast—CYP1A2—nipple—skin cancer	2.43e-05	0.0402	CbGeAlD
Zafirlukast—CYSLTR2—Signaling Pathways—MC1R—skin cancer	2.34e-05	0.00471	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—GLI1—skin cancer	2.31e-05	0.00464	CbGpPWpGaD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.28e-05	0.00458	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—PTCH2—skin cancer	2.25e-05	0.00452	CbGpPWpGaD
Zafirlukast—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	2.2e-05	0.00442	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—SUFU—skin cancer	2.19e-05	0.0044	CbGpPWpGaD
Zafirlukast—PTGS1—nipple—skin cancer	2.11e-05	0.0348	CbGeAlD
Zafirlukast—CYSLTR1—GPCR downstream signaling—PTGER4—skin cancer	1.99e-05	0.004	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—SHH—skin cancer	1.96e-05	0.00394	CbGpPWpGaD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.94e-05	0.00389	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.91e-05	0.00383	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—PTCH1—skin cancer	1.86e-05	0.00373	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—SMO—skin cancer	1.86e-05	0.00373	CbGpPWpGaD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.85e-05	0.00372	CbGpPWpGaD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.83e-05	0.00369	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—PTGER4—skin cancer	1.81e-05	0.00363	CbGpPWpGaD
Zafirlukast—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.79e-05	0.00359	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—GLI2—skin cancer	1.7e-05	0.00342	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—SHH—skin cancer	1.67e-05	0.00336	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—RASA1—skin cancer	1.66e-05	0.00333	CbGpPWpGaD
Zafirlukast—CYP2C8—Arachidonic acid metabolism—PTGS2—skin cancer	1.64e-05	0.0033	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—MC1R—skin cancer	1.62e-05	0.00326	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—PTGS2—skin cancer	1.62e-05	0.00325	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—GLI1—skin cancer	1.6e-05	0.00322	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—SMO—skin cancer	1.58e-05	0.00318	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—PTCH1—skin cancer	1.58e-05	0.00318	CbGpPWpGaD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.58e-05	0.00317	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—PTGER4—skin cancer	1.54e-05	0.0031	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—SUFU—skin cancer	1.52e-05	0.00305	CbGpPWpGaD
Zafirlukast—PTGS1—connective tissue—skin cancer	1.49e-05	0.0247	CbGeAlD
Zafirlukast—ABCG2—mammalian vulva—skin cancer	1.47e-05	0.0244	CbGeAlD
Zafirlukast—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	1.47e-05	0.00295	CbGpPWpGaD
Zafirlukast—PTGS1—epithelium—skin cancer	1.42e-05	0.0234	CbGeAlD
Zafirlukast—CYSLTR2—Signaling Pathways—FOXO4—skin cancer	1.36e-05	0.00274	CbGpPWpGaD
Zafirlukast—PTGS1—skin of body—skin cancer	1.35e-05	0.0223	CbGeAlD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.34e-05	0.0027	CbGpPWpGaD
Zafirlukast—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	1.34e-05	0.00269	CbGpPWpGaD
Zafirlukast—CYP2C8—female reproductive system—skin cancer	1.3e-05	0.0215	CbGeAlD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.28e-05	0.00258	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.23e-05	0.00247	CbGpPWpGaD
Zafirlukast—PTGS1—mammalian vulva—skin cancer	1.23e-05	0.0203	CbGeAlD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	1.22e-05	0.00246	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—SHH—skin cancer	1.16e-05	0.00233	CbGpPWpGaD
Zafirlukast—CYP2C9—female reproductive system—skin cancer	1.15e-05	0.0191	CbGeAlD
Zafirlukast—CYSLTR1—Signaling Pathways—RASA1—skin cancer	1.15e-05	0.00231	CbGpPWpGaD
Zafirlukast—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	1.14e-05	0.0023	CbGpPWpGaD
Zafirlukast—CYP2E1—lymphoid tissue—skin cancer	1.13e-05	0.0187	CbGeAlD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.1e-05	0.00221	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—PTCH1—skin cancer	1.1e-05	0.0022	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—SMO—skin cancer	1.1e-05	0.0022	CbGpPWpGaD
Zafirlukast—CYP2E1—female reproductive system—skin cancer	1.09e-05	0.0181	CbGeAlD
Zafirlukast—CYSLTR1—Signaling Pathways—PTGER4—skin cancer	1.07e-05	0.00215	CbGpPWpGaD
Zafirlukast—PTGS1—female reproductive system—skin cancer	1.05e-05	0.0174	CbGeAlD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1e-05	0.00201	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	9.51e-06	0.00191	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—FOXO4—skin cancer	9.43e-06	0.0019	CbGpPWpGaD
Zafirlukast—CYP2E1—head—skin cancer	9.13e-06	0.0151	CbGeAlD
Zafirlukast—CYSLTR2—Signaling Pathways—TERT—skin cancer	9.09e-06	0.00183	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PLIN2—skin cancer	8.83e-06	0.00178	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	8.82e-06	0.00177	CbGpPWpGaD
Zafirlukast—PTGS1—head—skin cancer	8.8e-06	0.0145	CbGeAlD
Zafirlukast—CYP3A4—female reproductive system—skin cancer	8.8e-06	0.0145	CbGeAlD
Zafirlukast—CYP2D6—female reproductive system—skin cancer	8.66e-06	0.0143	CbGeAlD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	8.56e-06	0.00172	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PLIN2—skin cancer	8.49e-06	0.00171	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	8.18e-06	0.00165	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—NRAS—skin cancer	7.66e-06	0.00154	CbGpPWpGaD
Zafirlukast—ABCG2—lymph node—skin cancer	7.39e-06	0.0122	CbGeAlD
Zafirlukast—CYP2D6—head—skin cancer	7.23e-06	0.012	CbGeAlD
Zafirlukast—CYSLTR2—Signaling Pathways—BRAF—skin cancer	7.2e-06	0.00145	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—CSPG4—skin cancer	7.12e-06	0.00143	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	6.95e-06	0.0014	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—CSPG4—skin cancer	6.84e-06	0.00138	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—KRAS—skin cancer	6.59e-06	0.00132	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PLIN2—skin cancer	6.34e-06	0.00128	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TERT—skin cancer	6.3e-06	0.00127	CbGpPWpGaD
Zafirlukast—PTGS1—lymph node—skin cancer	6.16e-06	0.0102	CbGeAlD
Zafirlukast—CYSLTR2—Signaling by GPCR—HRAS—skin cancer	5.6e-06	0.00113	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PLIN2—skin cancer	5.48e-06	0.0011	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—IL6—skin cancer	5.36e-06	0.00108	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—NRAS—skin cancer	5.31e-06	0.00107	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—CSPG4—skin cancer	5.11e-06	0.00103	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—BRAF—skin cancer	4.99e-06	0.001	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PLIN2—skin cancer	4.89e-06	0.000984	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—ENO2—skin cancer	4.84e-06	0.000973	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—ENO2—skin cancer	4.65e-06	0.000935	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—KRAS—skin cancer	4.57e-06	0.000918	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—NRAS—skin cancer	4.52e-06	0.000909	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PLIN2—skin cancer	4.5e-06	0.000905	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PLIN2—skin cancer	4.46e-06	0.000897	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—CSPG4—skin cancer	4.42e-06	0.000888	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—CSPG4—skin cancer	3.94e-06	0.000793	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—KRAS—skin cancer	3.89e-06	0.000783	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—HRAS—skin cancer	3.88e-06	0.000781	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PLIN2—skin cancer	3.81e-06	0.000766	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—IL6—skin cancer	3.72e-06	0.000747	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.64e-06	0.000731	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CSPG4—skin cancer	3.63e-06	0.000729	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CSPG4—skin cancer	3.6e-06	0.000723	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—ENO2—skin cancer	3.47e-06	0.000699	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—TP53—skin cancer	3.46e-06	0.000696	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—HRAS—skin cancer	3.31e-06	0.000665	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—IL6—skin cancer	3.17e-06	0.000637	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—NRAS—skin cancer	3.13e-06	0.00063	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CSPG4—skin cancer	3.07e-06	0.000618	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—ENO2—skin cancer	3e-06	0.000604	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PLIN2—skin cancer	2.94e-06	0.000592	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—ERCC2—skin cancer	2.81e-06	0.000565	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—ERCC2—skin cancer	2.7e-06	0.000543	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—KRAS—skin cancer	2.7e-06	0.000542	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—ENO2—skin cancer	2.68e-06	0.000539	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—ENO2—skin cancer	2.47e-06	0.000496	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—ENO2—skin cancer	2.44e-06	0.000491	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TP53—skin cancer	2.4e-06	0.000482	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—CSPG4—skin cancer	2.37e-06	0.000477	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.35e-06	0.000472	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—HRAS—skin cancer	2.29e-06	0.000461	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—IL6—skin cancer	2.19e-06	0.000441	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.1e-06	0.000422	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—ENO2—skin cancer	2.09e-06	0.00042	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—ERCC2—skin cancer	2.02e-06	0.000406	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.91e-06	0.000384	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—ERCC2—skin cancer	1.74e-06	0.000351	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PTGS2—skin cancer	1.69e-06	0.000339	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.63e-06	0.000328	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PTGS2—skin cancer	1.62e-06	0.000326	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—ENO2—skin cancer	1.61e-06	0.000324	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—ERCC2—skin cancer	1.56e-06	0.000313	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—ERCC2—skin cancer	1.43e-06	0.000288	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—ERCC2—skin cancer	1.42e-06	0.000285	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—ERCC2—skin cancer	1.21e-06	0.000244	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PTGS2—skin cancer	1.21e-06	0.000243	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PTGS2—skin cancer	1.05e-06	0.00021	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—ERCC2—skin cancer	9.36e-07	0.000188	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PTGS2—skin cancer	9.34e-07	0.000188	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PTGS2—skin cancer	8.59e-07	0.000173	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PTGS2—skin cancer	8.51e-07	0.000171	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PTGS2—skin cancer	7.27e-07	0.000146	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PTGS2—skin cancer	5.61e-07	0.000113	CbGpPWpGaD
